X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Jan123 (naltrexone) is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs.
Lead Product(s): Naltrexone
Therapeutic Area: Neurology Product Name: Jan123
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Neurology Product Name: JAN 101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Neurology Product Name: JAN 101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Jan123 (naltrexone) is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs.
Lead Product(s): Naltrexone
Therapeutic Area: Neurology Product Name: JAN123
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Soin Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 10, 2023
Details:
Recent studies have in fact suggested that PAD is a microvascular disease, so the observation that JAN101 (Sodium nitrite) improves microvascular and nerve function is crucial in treating this disease.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Sale of GeoTraq, a wholly-owned subsidiary of JanOne to SPYR Technologies will help main business continue to fund the necessary clinical trials for JAN101 (TV1001SR), a slow-release formulation of sodium nitrite used for treatment for peripheral artery disease.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPYR Technologies
Deal Size: $13.5 million Upfront Cash: $13.5 million
Deal Type: Divestment May 31, 2022
Details:
JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of Peripheral Artery Disease (PAD).
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
The primary endpoint will be the ability of patients to walk without pain or muscle fatigue as a result of vascular function restored by JAN101.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
JAN101 is intended to address the 8.5 million Americans who may have PAD. One of the more encouraging outcomes from patients who participated in early Phase 1 and Phase 2a trials of JAN101 was a reported reduction in associated PAD pain.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JAN101 is highly selective, acting only in damaged tissue.
Lead Product(s): Sodium Nitrite
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JAN101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
